GlassScriptPhysician profile
Kimberly Peters
NPI 1922304369
$759.88
in general payments reported to CMS, 2019-2025
21 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $112 · 2023: $209 · 2024: $185 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $83.58 | 2021-2024 | Freestyle Libre |
| Pfizer INC. | $70.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $67.58 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $66.63 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $64.86 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.44 | 2025 | Caplyta |
| Astellas Pharma US INC | $46.53 | 2021-2024 | Veozah |
| Amgen INC. | $46.21 | 2021-2025 | Evenity, Repatha, Otezla |
| Edwards Lifesciences Corporation | $29.99 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $29.89 | 2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2021-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $27.87 | 2021-2022 | |
| Viatris Specialty LLC | $23.85 | 2025 | Yupelri |
| Mylan Specialty L.P. | $22.21 | 2024 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $16.78 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.18 | 2022 | |
| Novo Nordisk INC | $16.11 | 2023 | Wegovy |
| Lilly USA, LLC | $15.22 | 2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $14.19 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $12.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.